Why HCW Biologics Inc.’s (HCWB) Stock Is Up 8.74%
As of Thursday, June 05, HCW Biologics Inc.’s HCWB share price has surged by 8.74%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Commentary & Analysis
Why HCW Biologics Inc.’s (HCWB) Stock Is Down 6.72%
As of Wednesday, June 04, HCW Biologics Inc.’s HCWB share price has dipped by 6.72%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Hcw Biologics Inc (HCWB) Stock a Good Investment?
Learn more about Hcw Biologics Inc's (HCWB) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Zach Banning
Financial Summary
| Share Statistics | HCWB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.3 | $219.9 | 2% |
|
| Shares Out (Mil) | 1.3 | 54.1 | 6% |
|
| Institutional Ownership | 38.1% | 92.9% | 16% |
|
| Float (Mil) | 2.1 | 41.4 | 6% |
|
| Beta | 2.42 | 0.95 | 95% |
|
| Avg Daily Volume (000s) | 42 | 522 | 28% |
|
| Price Change (52-week) |
(94.9%) | 44.7% | 4% |
|
| Growth | HCWB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (6.6%) | (10.1%) | 32% |
|
| EPS (5yr) | 29.2% | 15.8% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.4%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HCWB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $38 | 7% |
|
| Net Income (TTM) (Mil) | ($6) | ($44) | 32% |
|
| EPS (TTM) | ($27.185) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($35) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $9 | $166 | 7% |
|
| Valuation | HCWB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.22 | 2.06 | 4% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | HCWB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 95.9% | 67.3% | 96% |
|
| Net Margin | (83.0%) | (61.0%) | 8% |
|
| ROA | (20.1%) | (47.5%) | 20% |
|
| ROE | (151.4%) | (52.7%) | 6% |
|
| Liabilities to Assets | 72.3% | 29.6% | 68% |
|
| F-Score | 4 | 3 | 33% |
|
HCW Biologics Inc. did not pass any screens on 11/6/2026.
